CYP2C8 GWAS Links CYP2C19 to Plavix Response; Randomized-Controlled Trial, PGx Consortium to Come Premium Following the GWAS, researchers plan to conduct a prospective, randomized-controlled trial and form a pharmacogenomics consortium specifically focused on validating and discovering new gene-response variants for clopidogrel. Breaking News BeiGene, CLL Society Partner to Promote Biomarker Testing in CLL, SLL Abselion Closes £6.6M Series A Round Metastatic Cancer Development Dialed Down by Extracellular Vesicle DNA LGC Acquires German Quality Controls Maker DiaMex Reveal Genomics Studying HER2DX Test Impact on Breast Cancer Treatment Decisions
